Research programme: eye disorders therapy - CSL

Drug Profile

Research programme: eye disorders therapy - CSL

Alternative Names: Recombinant antibody therapeutics research programme - CSL

Latest Information Update: 19 Apr 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CSL
  • Developer CSL; Flinders University
  • Class Antibodies; Proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Eye disorders

Most Recent Events

  • 13 Jul 2007 Late-stage preclinical development is ongoing
  • 05 Oct 2004 Preclinical trials in Eye disorders in Australia (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top